tirzepatide weight regain study after the withdrawal of (Zepbound) may wipe out many of the cardiometabolic gains made during weight loss, a post-hoc analysis of the SURMOUNT-4 trial indicated. Read more at: https://www.medpagetoday.com/endocrinology/obesity Tirzepatide for the Maintenance of

A (Yael Horwitz): Many users (40% in our member survey) take compounded GLP-1s, which often dont appear in claims data, which makes it harder for employers and plans to track ROI or manage spend effectively

Neuron 72 , 257268 (2011)

For patients without a gallbladder, the experience of these side effects may differ in character or intensity due to altered bile flow and fat digestion patterns

No axillary lymphadenopathy, joint swelling, or skin rash was noted

It is estimated that 43% of the non-diabetic adult US population in 2025 is obese

doi: 10.1001/jama.2019.2942 30 PratleyRAmodATetens HoffSKadowakiTLingvayINauckMet al